Compare Cronos Group Inc (CRON) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Dolby Laboratories, Inc. — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Dolby Laboratories, Inc. trades at $58.69 (market cap $5.47B). The key difference: Dolby Laboratories, Inc. is far larger — about 4.6× Cronos Group Inc's market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Dolby Laboratories, Inc. for 98 Days on average.
| CRON | DLB | |
|---|---|---|
Market Cap | $1.18B | $5.47B |
Volume | 968,037 | 1,058,284 |
Sector | Health | Technology |
52-Week High | $3.55 | $70.09 |
52-Week Low | $2.30 | $48.51 |
Typical Hold Time | 22 Days | 98 Days |
Enterprise Value | $387.62M | $4.85B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $146.59M in 2025, but net income was -$9.45M. Recent Q2 2026 earnings beat expectations with EPS of $0.09. The company held its first Investor Day in September 2026, highlighting international expansion and cash flow focus.
Outlook is mixed: strong revenue growth and a solid balance sheet with no debt support upside, but profitability remains inconsistent. Risks include cash flow volatility and competitive pressures. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty amid expansion efforts.
DLB trades at $58.90, up 0.94% with bearish technical signals but strong fundamentals including 87.61% gross margins and consistent earnings beats. Recent expansion with Meta and leadership transition to Marc Whitten highlight growth initiatives. Cash flow improved significantly to $215.61M in 2025 from negative trends.
Analyst consensus targets $90.33 (53% upside) with 47% buy ratings, though technical indicators signal caution. Key risks include licensing volatility and execution during leadership change. Revenue stability and premium valuation at 24.87 P/E support long-term case if growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
